Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

Abstract Background Signaling through VEGF/VEGFR induces cancer angiogenesis and affects immune cells. An increasing number of studies have recently focused on combining anti-VEGF/VEGFR agents and immune checkpoint inhibitors (ICIs) to treat cancer in preclinical and clinical settings. BD0801 is a h...

Full description

Bibliographic Details
Main Authors: Liting Xue, Xingyuan Gao, Haoyu Zhang, Jianxing Tang, Qian Wang, Feng Li, Xinxin Li, Xiaohong Yu, Zhihong Lu, Yue Huang, Renhong Tang, Wenqing Yang
Format: Article
Language:English
Published: BMC 2021-10-01
Series:BMC Cancer
Subjects:
Anti-VEGF monoclonal antibody
Immune checkpoint blockade
Combination treatment
Tumor microenvironment
Antitumor synergy
Online Access:https://doi.org/10.1186/s12885-021-08859-5

Internet

https://doi.org/10.1186/s12885-021-08859-5

Similar Items